A5069854182- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Research Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Genetic factors in colorectal cancer
- Radiomics and Machine Learning in Medical Imaging
- Chronic Lymphocytic Leukemia Research
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Medical Imaging and Pathology Studies
- PI3K/AKT/mTOR signaling in cancer
- Melanoma and MAPK Pathways
- Chromatin Remodeling and Cancer
- Medical Imaging Techniques and Applications
- Cancer therapeutics and mechanisms
- Computational Drug Discovery Methods
- Advanced Breast Cancer Therapies
- Sarcoidosis and Beryllium Toxicity Research
- Pleural and Pulmonary Diseases
- Ovarian cancer diagnosis and treatment
Brigham and Women's Hospital
2016-2025
Dana-Farber Cancer Institute
2016-2025
Dana-Farber Brigham Cancer Center
2016-2025
Harvard University
2016-2025
Canon (Japan)
2019-2024
Canon Medical Systems Corporation (Japan)
2019-2024
International Association for the Study of Lung Cancer
2024
Osaka University
2024
Mallinckrodt (United States)
2024
University of Wisconsin–Madison
2023
Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine efficacy PD-1 inhibitors these subgroups. Objective response rates to blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) (P < 0.001) Stand Up To Cancer (SU2C) cohort (174 patients) with LUAC patients treated nivolumab CheckMate-057 phase III...
Cigarette smoking is associated with emphysema and radiographic interstitial lung abnormalities. The degree to which abnormalities are reduced total capacity the extent of not known.
Immune-related response criteria (irRC) was developed to adequately assess tumor immunotherapy. The irRC are based on bidimensional measurements, as opposed unidimensional measurements defined by Response Evaluation Criteria in Solid Tumors, which has been widely used solid tumors. We aimed compare assessment versus patients with advanced melanoma treated ipilimumab.Fifty-seven ipilimumab a phase II, expanded access trial were studied. Bidimensional measurement records prospectively...
Abstract Purpose: Investigate the clinical characteristics, radiographic patterns, and treatment course of PD-1 inhibitor–related pneumonitis in advanced cancer patients. Experimental Design: Among patients with melanoma, lung cancer, or lymphoma treated trials nivolumab, we identified those who developed pneumonitis. Chest CT scans were reviewed to assess extent, distribution, patterns Results: 170 10 different 20 (10 6 lymphoma, 4 cancer) Five received nivolumab monotherapy, 15 combination...
BACKGROUND. Comprehensive genomic profiling of a patient's cancer can be used to diagnose, monitor, and recommend treatment. Clinical implementation tumor in an enterprise-wide, unselected patient population has yet reported. METHODS. We deployed hybrid-capture massively parallel sequencing assay (OncoPanel) for all adult pediatric patients at our combined centers. Results were categorized by pathologists based on actionability. report the results first 3,727 tested. RESULTS. Our cohort...
A common promoter polymorphism (rs35705950) in MUC5B, the gene encoding mucin 5B, is associated with idiopathic pulmonary fibrosis. It not known whether this interstitial lung disease general population.We performed a blinded assessment of abnormalities detected 2633 participants Framingham Heart Study by means volumetric chest computed tomography (CT). We evaluated relationship between and genotype at rs35705950 locus.Of CT scans that were evaluated, present 177 (7%). Participants such more...
<h3>Importance</h3> Interstitial lung abnormalities have been associated with lower 6-minute walk distance, diffusion capacity for carbon monoxide, and total capacity. However, to our knowledge, an association mortality has not previously investigated. <h3>Objective</h3> To investigate whether interstitial are increased mortality. <h3>Design, Setting, Population</h3> Prospective cohort studies of 2633 participants from the FHS (Framingham Heart Study; computed tomographic [CT] scans obtained...
Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and Radiologists Need KnowMizuki Nishino1, Jyothi P. Jagannathan, Nikhil H. Ramaiya Annick D. Van den AbbeeleAudio Available | Share
Abstract Purpose: BRAF mutations are found in a subset of non–small cell lung cancers (NSCLC). We examined the clinical characteristics and treatment outcomes patients with NSCLC harboring mutations. Experimental Design: Using DNA sequencing, we successfully screened 883 for between July 1, 2009 16, 2012. Baseline were compared without Wild-type controls consisted somatic alteration BRAF, KRAS, EGFR, ALK. In vitro studies assessed biologic properties selected non-V600E identified from NSCLC....
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients Methods Atezolizumab data from clinical trials non–small-cell lung cancer, metastatic urothelial carcinoma, renal cell melanoma were evaluated. Modifications...
BackgroundIn non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment the PD-1 inhibitor pembrolizumab improves survival compared platinum-doublet chemotherapy. Whether higher PD-L1 levels within range 50%–100% predict for even greater benefit to is currently unknown.Patients and methodsIn this multicenter retrospective analysis, we analyzed impact overall response rate (ORR), median progression-free (mPFS), (mOS) in patients...
The relationship between the development and/or progression of interstitial lung abnormalities (ILA) and clinical outcomes has not been previously investigated.To determine risk factors for, consequences of, having ILA in participants from Framingham Heart Study.ILA were assessed 1,867 who had serial chest computed tomography (CT) scans approximately 6 years apart. Mixed effect regression (and Cox) models used to assess association pulmonary function decline mortality).During follow-up...
MET exon 14 alterations are actionable oncogenic drivers. Durable responses to inhibitors observed in patients with advanced 14-altered lung cancers prospective trials. In contrast, the activity of immunotherapy, PD-L1 expression and tumor mutational burden (TMB) these tumors not well characterized.Patients any stage treated at two academic institutions were identified. A review clinicopathologic molecular features, an analysis response single-agent or combination immune checkpoint...
PURPOSE Baseline use of corticosteroids is associated with poor outcomes in patients non–small-cell lung cancer (NSCLC) treated programmed cell death-1 axis inhibition. To approach the question causation versus correlation for this association, we examined immunotherapy depending on whether were administered cancer-related palliative reasons or cancer-unrelated indications. PATIENTS AND METHODS Clinical NSCLC who received ≥ 10 mg prednisone compared 0 to < prednisone. RESULTS Of 650...
Importance Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is lack consensus about the optimal TMB threshold that best discriminates improved outcomes immune checkpoint inhibitor therapy among patients with non–small cell lung cancer (NSCLC). Objectives To determine association between increasing levels and across clinically relevant programmed death ligand–1 (PD-L1) NSCLC. Design, Setting, Participants...
Ipilimumab is a promising novel immunotherapy agent and associated with variety of immune-related adverse events (irAE). The purpose this study was to investigate the manifestations irAEs on body imaging in patients advanced melanoma treated ipilimumab. One-hundred forty-seven (59 women, 88 men; median age, 64.5 years) ipilimumab were studied. All had baseline at least one follow-up chest/abdomen/pelvis CT or PET/CT during therapy, which reviewed by consensus two radiologists blinded...
Interstitial lung disease (ILD), a leading cause of morbidity and mortality in rheumatoid arthritis (RA), is highly prevalent, yet RA-ILD underrecognized.To identify clinical risk factors, autoantibodies, biomarkers associated with the presence RA-ILD.Subjects enrolled Brigham Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) American College Rheumatology (ACR) cohorts were evaluated for ILD. Regression models used to assess association between variables interest RA-ILD....
Rationale: Interstitial lung abnormalities (ILA) are radiologic on chest computed tomography scans that have been associated with an early or mild form of pulmonary fibrosis. Although ILA progression, it is not known if specific imaging patterns progression risk mortality.Objectives: To determine the role death and progression.Methods: (and pattern) were assessed in 5,320 participants from AGES-Reykjavik Study, was 3,167 participants. Multivariable logistic regression used to assess factors...
To evaluate rheumatoid arthritis (RA) disease activity and risk of RA-associated interstitial lung (RA-ILD).We investigated RA-ILD using the Brigham RA Sequential Study (BRASS, 2003-2016). All patients were diagnosed as having according to accepted criteria. Disease Activity Scores in 28 joints (DAS28) covariate data measured prospectively at annual study visits. Diagnosis was determined by review images from clinically indicated chest computed tomography scans. We analyzed without baseline....